Journal of Diabetes Research

Journal of Diabetes Research / 2013 / Article
Special Issue

Chronic Vascular Complications in Diabetes

View this Special Issue

Research Article | Open Access

Volume 2013 |Article ID 185172 |

Juan Xiao, Jun Song, Vida Hodara, Allen Ford, Xing Li Wang, Qiang Shi, Li Chen, John L. VandeBerg, "Protective Effects of Resveratrol on TNF- -Induced Endothelial Cytotoxicity in Baboon Femoral Arterial Endothelial Cells", Journal of Diabetes Research, vol. 2013, Article ID 185172, 9 pages, 2013.

Protective Effects of Resveratrol on TNF- -Induced Endothelial Cytotoxicity in Baboon Femoral Arterial Endothelial Cells

Academic Editor: Weiping Jia
Received05 Jan 2013
Revised27 Feb 2013
Accepted01 Mar 2013
Published31 Mar 2013


Endothelial injury induced by inflammatory factors plays a critical role in the pathogenesis of cardiovascular disease. Endothelial cell (EC) apoptosis, proliferation, migration, and cellular adhesion molecule (CAM) expression contribute to the development of atherosclerosis. We investigated the effects of resveratrol (0.1–100 μM) on the proliferation, migration, and CAM expression of primary cultures of baboon arterial endothelial cells (BAECs). In addition, we tested its effects under normal conditions as well as under inflammatory conditions induced by tumour necrosis factor- (TNF- ) administered either by cotreatment, pretreatment, or posttreatment. Immunocytochemistry, MTT, wound-healing, and flow cytometry assays were performed. The resveratrol treatment significantly enhanced BAEC proliferation and attenuated TNF- -induced impairment of proliferation at the optimal doses of 1–50 µM. Resveratrol at a high dose (100 μM) and TNF- impaired BAEC migration, while low doses of resveratrol (1–50 μM) attenuated TNF- -induced impairment of BAEC migration. Moreover, resveratrol inhibited TNF- -induced ICAM-1 and VCAM-1 expression. Taken together, our results suggest that the resveratrol protects BAECs after inflammatory stimulation as well as ameliorates inflammatory effects at low concentrations. Consequently, resveratrol should be considered as a candidate drug for the prevention and treatment of inflammatory vascular diseases.

1. Introduction

Endothelial cell (EC) cytotoxicity induced by inflammatory factors plays a key role in the pathogenesis of cardiovascular disease. Tumour necrosis factor (TNF)- , a pleiotropic proinflammatory cytokine involved in the pathogenesis of inflammatory, and vascular disease, can promote endothelial cell apoptosis and inflammation [1] by directly activating a number of cellular stress-sensitive pathways including nuclear factor-kappa B (NF- B) and mitogen-activated protein kinase (MAPK) [2]. These subsequently contribute to endothelial cell injury and cellular dysfunction [3]. Therefore, the inhibition of TNF- -induced endothelial cell cytotoxicity can be important in preventing the cardiovascular disease and inhibiting its progression.

The resveratrol possesses many pharmacological properties including anticancer [4], anti-inflammation [5], and cardioprotective effects [6]. The resveratrol exerts direct cardiovascular protective effects by improving myocardial perfusion, reducing oxidant stress, and inhibiting platelet aggregation [79]. Recent studies have shown that resveratrol acts partially through the inhibition of cellular apoptosis and inflammation by inhibiting the NF- B pathway [10, 11]. The beneficial effects of resveratrol on suggest that it could be an important pharmacological target for the treatment of cardiovascular disease. However, resveratrol has cell-specific [12, 13] and dose-dependent [14] effects on cellular proliferation or apoptosis. Studies of a wide range of concentrations of resveratrol administered to a uniform population of ECs are lacking. Such studies are required to comprehend the diverse and sometimes contradictory cellular effects of resveratrol [15]. Previous studies demonstrated that resveratrol has biphasic properties in relation to its concentration on EC proliferation, with no effects at low concentrations (0.1–25  M) and induced apoptosis at high doses (such as 100  M) in human umbilical vein endothelial cells (HUVECs) [16].

The baboon is a well-characterized model for human biomedical studies including cardiovascular diseases [17, 18]. In the present study, we investigated the effects of a wide range of concentrations of resveratrol on cultured primary baboon arterial endothelial cells (BAECs) under normal conditions as well as under TNF- -induced inflammatory condition in which cells underwent cotreatment, pretreatment, or posttreatment with resveratrol.

2. Methods

2.1. Materials

Unless otherwise indicated, all the reagents used in this study and their sources were as follows: resveratrol and 3-(4,5-dimethyl-2-thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (Sigma, St. Louis, MO); anti-CD62E (E-selectin) (R&D Systems, Minneapolis, MN, Clone BB1G-E5); anti-CD54 (intercellular adhesion molecule-1) (BD Biosciences, San Jose, CA, Clone HA58); anti-CD106 (vascular cell adhesion molecule-1) (US Biological, Swampscott, MA, Clone 5K26T); cell culture media and supplies (Invitrogen, Carlsbad, CA).

2.2. BAEC Isolation and Culture

BAECs were isolated from baboon femoral arteries as previously described [17]. Briefly, a 2-3 cm segment of femoral artery was obtained under sterile surgical procedure by experienced veterinarians; procedures were approved by the Institutional Animal Care and Use Committee of Texas Biomedical Research Institute. The artery was incubated with 0.1% collagenase at 37°C for 15 min to digest extracellular tissue to allow the release of cells. The released cells were washed and seeded immediately on 1.0% gelatin-coated culture plates. Primary BAECs were cultured in F-12K growth medium supplemented with 20% foetal calf serum (FCS). Passages three and four of BAECs were used in this study. BAECs were treated with resveratrol at various concentrations in the presence or absence of TNF- (10 ng/mL) for different time periods.

2.3. Immunocytochemistry

Primary BAECs were seeded into Lab-Tek multiwell chamber slides (BD Falcon 8-well Culture Slides) [18], fixed with 200  L 4% formaldehyde at room temperature (RT) for 10 min and then blocked with 10% goat serum for 30 min at RT. Cells were then incubated with 300  L of 1 : 400 or 1 : 800 diluted primary antibody (vWF: Sigma, St. Louis, MO; VE-Cadherin: Cell Signaling Technology, Danvers, MA) in 1% BSA in phosphate buffered saline (PBS) overnight at 4°C and then with FITC-labelled secondary antibody in 1% BSA in PBS for 1 h at RT in the dark. DAPI (0.5  g/mL) was added for 5 min, and slides were mounted with 10  L/well antifade solution (Invitrogen, no. S36936) in 1× PBS. Slides were observed by fluorescence microscopy.

2.4. MTT Assay

Cells were seeded in 96-well plates at a density of 1000 cells/well in 2% FCS F-12K growth medium for 24 h and treated with resveratrol at the designated concentrations (0.1–100  mol/L) in the presence or absence of TNF- (10 ng/mL) for different time periods. Treated cells were incubated with 20  L (1 mg/mL) MTT for 4 h at 37°C to form formazan crystals by reacting with metabolically active cells. Subsequently, the formazan crystals were solubilized with 150  L DMSO. The absorbance of each well was measured at A570 nm using a microplate reader. Cell viability was measured by the absorbance, normalized to cell numbers, incubated in control medium (considered 100%), and then determined relative to the control.

2.5. Wound-Healing Assay

Nearly confluent cell monolayers were “wounded” in a cross-shaped pattern with a sterile 200  L pipette tip. The medium and dislodged cells were aspirated, and plates were replenished by either endothelial cell growth medium (ECGM) without FCS, which served as the control or by medium containing resveratrol (0.1–100  M) with or without TNF- (10 ng/mL). Images of the wound healing at 15 h were captured in the same scratched area localized to the right of the cross-shaped scratch with a 40x objective (Olympus IX70 microscope) and quantified by measuring the wound area with Image-Pro Plus software 6.0. Three fields per well were evaluated, and all experiments were performed in quadruplicate. Results were reported as the percentage of wound healing using the equation: % wound healing = [1 − (wound area at T15 h /wound area at T0 h)] × 100, where T0 h is the time immediately following wounding.

2.6. Flow Cytometry

The expression of proportions of cell specific cellular adhesion molecules was quantified by standard immunofluorescence cell sorting techniques [19, 20]. The following antibodies were used in this study: anti-human CD62E (clone BBIG-E5), anti-human CD54 (clone HA58), and anti-human CD106 (clone 5K267). Unstained and isotype controls were used to determine background staining. Flow cytometry analysis was performed using Cyan ADP (Becton Dickinson, San Jose, CA). Mean fluorescence intensity (MFI) values in respective gates were used to represent antigen expression. All experiments were performed three times and each time in triplicate.

2.7. Statistical Analysis

All quantitative variables were expressed as means SEM from at least three separate experiments. Comparisons between groups were made using one-way ANOVA followed by Dunnett’s post hoc test. To evaluate the difference of two groups, we used two-tailed Student’s -test. was considered statistically significant. SPSS version 17.0 (SPSS Inc., Chicago, IL) was used for statistical analyses.

3. Results

3.1. Primary BAEC Culture and Identification

Primary baboon arterial had a typical cobblestone shape (Figures 1(a) and 1(b)) and took 3–7 days to reach confluence depending on cell seeding density and number of passages. BAECs maintained proliferation ability for 30 populations or 10 passages, with stable expression of cellular adhesion molecules. Prior to their use, we stained BAECs with endothelial specific marker VE-cadherin (Figure 1(c)) and vWF (Figure 1(d)) to ensure the purity and healthy condition of the cells.

3.2. Resveratrol Enhances BAEC Proliferation and Attenuates TNF- -Induced Impairment

We first tested the effect of various concentrations of resveratrol (0.1–100  M) on the growth of primary BAECs (Figure 2(a)) and the extent to which resveratrol affected BAEC proliferation impaired by TNF- when administered as cotreatment (Figure 2(b)), pretreatment (Figure 2(c)), or posttreatment (Figure 2(d)). Resveratrol (0.1–100  M) highly significantly enhanced EC proliferation after 24 h incubation in the optimal range of 10–50  M ( , ) (Figure 2(a)). TNF- treatment alone (10 ng/mL) for 24 h significantly decreased ( ) BAEC proliferation by comparison with controls (Figure 2(b)). However, cotreatment with resveratrol at 1–50  M alleviated cytotoxicity induced by TNF- ( ). No effects were detected at 1 or 100  M, suggesting a dose-dependent effect of resveratrol on baboon ECs subjected to inflammatory conditions. Pretreatment with resveratrol (0.1–100  M) (Figure 2(c)) for 24 h also attenuated impairment of BAEC proliferation caused by incubation with TNF- for 4 h ( ), especially at doses of 1–50  M ( ). Additionally, posttreatment with resveratrol (0.1–100  M) (Figure 2(d)) for 24 h attenuated TNF- -induced impairment of BAEC proliferation, with the optimal dose being 10  M ( , ). Together, the data indicated that the resveratrol could enhance primary baboon EC proliferation and could prevent cytotoxicity induced by TNF- .

3.3. Resveratrol Attenuated BAEC Migration Impaired by TNF-

We investigated whether resveratrol could affect BAEC migration with or without TNF- treatment. As shown in Figure 3(a), resveratrol at a low concentration (10  M; ) increased wounded BAEC migration by comparison with controls, but, at a high concentration (100  M; ), it decreased the BAEC migration during 15 h. No effect was observed at concentrations of 0.1, 1, and 50  M. As shown in Figure 3(b), TNF- ( ) dramatically impaired BAEC migration at 15 h compared with controls, while resveratrol (1–50  M) in the presence of TNF- significantly increased the BAEC migration rate by comparison with TNF- treatment alone ( ). No protective effect of 100  M resveratrol was observed.

3.4. Resveratrol Inhibits TNF- -Induced Expression of VCAM-1 (CD106) and ICAM-1 (CD54) in BAECs

To investigate whether resveratrol affected the level of inducible cell adhesion molecule expression of E-selectin (CD62E), ICAM-1 (CD54), and VCAM-1 (CD106), BAECs were analysed by flow cytometry. BAECs were cotreated (Figures 4(a) and 4(b)), pretreated (Figure 4(c)), or posttreated (Figure 4(d)) with resveratrol (10, 50  M) and TNF- . E-selectin, ICAM-1, and VCAM-1 expression on BAECs were significantly increased by TNF- (10 ng/mL) stimulation at 4 h by comparison with controls ( , Figure 4(a)). ICAM-1 and VCAM-1, but not E-selectin, remained elevated after 24 h ( , Figure 4(b)). Resveratrol cotreatment did not inhibit the elevation in CAM expression elicited by TNF- at 4 h (Figure 4(a)), but the expression of ICAM-1 and VCAM-1 significantly decreased in BAECs treated for 24 h with resveratrol (10, 50  M) and TNF- (10 ng/mL) by comparison with TNF- treatment alone (10 ng/mL, , Figure 4(b)). Pretreatment with resveratrol (10, 50  M) for 24 h (Figure 4(c)) inhibited the elevation of ICAM-1 and VCAM-1 expression induced by TNF- stimulation ( ). BAECs that were treated with TNF- for 4 h and then incubated with resveratrol (10, 50  M, posttreatment) for 24 h (Figure 4(d)) exhibited significantly attenuated ICAM-1 (50  M) and VCAM-1 (10, 50  M) expression compared with controls ( , ).

4. Discussion

Recently, resveratrol has gained considerable attention because of its anticancer [4], anti-inflammatory [5], antidiabetes [21], and cardiovascular protective effects [6]. These properties have been reported in studies using experimental mouse, rat, and swine models [8, 22], but not primate models. Moreover, the effects of resveratrol on human are influenced by their vascular origin [23].

In this study, we investigated the effect of resveratrol on primary baboon femoral artery as an in vitro primate model. The advantages of this model are as follows. First, it is easier to obtain primary macrovascular ECs from baboons in comparison with humans. Second, baboons exhibit a high degree of genetic, biochemical, physiological, and anatomical similarity to humans, and more closely resemble humans in comparison with other species in the pathology of vascular diseases [18]. Third, we preferred BAECs because they are hyperresponsive to TNF- compared with venous ECs, and they may play a key role in macrovascular disease under adverse conditions [24]. Fourth, BAECs have similar responses to human aortic endothelial cells (HAECs) when stimulated with TNF- and thus provide an effective model for translating therapies to human clinical trials [25]. BAECs can be used at an early stage of disease that may closely mimic the inflammation responses of ECs in vivo. We have established a protocol for primary BAEC culture and previously performed fundamental investigations on their morphology and functions [20, 26]. Additionally, Mikula-Pietrasik et al. recently demonstrated that the resveratrol and its derivatives have cell-specific effects, which were confirmed by having different effects on the proliferation of human from different sources [15]. Thus, we selected BAECs as our model for in vitro studies as a prelude to in vivo studies.

Proliferation and migration of ECs may play a crucial role in vascular self-repair in normal physiological as well as pathological conditions. EC monolayer integrity is maintained via proliferation and migration of neighboring cells. We first investigated different experimental settings to verify the effects of resveratrol on BAEC proliferation under normal and inflammatory conditions. Resveratrol highly significantly enhanced BAEC proliferation at the optimal concentrations of 10–100  M, and it attenuated cellular impairment caused by TNF- treatment when administered to the cells as cotreatment, pretreatment, or post-treatment. Data concerning the influence of resveratrol on EC growth have not been completely consistent. Previous studies demonstrated that resveratrol induces increasing levels of apoptosis in with increasing concentration (25–100  M) and induces apoptosis at 100  M by cleavage of caspase 3 [16, 27], while low doses (0.1–25  M) had no effect. Csiszar et al. demonstrated that 10  M resveratrol prevented EC apoptosis induced by cigarette smoke extract [28]. Our results were partially consistent with those studies. Moreover, Ungvari et al. and Brito et al. showed that resveratrol at a concentration range of 1–100  M attenuated apoptosis mediated by oxidative stress (TNF- , oxidized LDL, and peroxynitrite) [29, 30]. With respect to EC apoptosis, the impact of resveratrol depends on concentration as well as cell source. Our study suggested that resveratrol is beneficial in protecting BAECs subjected to inflammatory stimulation as well as preventing cell injury at low concentrations.

The translation of in vitro and in vivo findings from experiments of animals and humans is thought to depend largely on parent resveratrol plasma concentration and bioavailability. The greatest plasma concentrations of resveratrol have been reported to be 2.36  M by Boocock et al. [31] and 4.2  M by Brown et al. [32] when 5 g of transresveratrol was administered to humans. However, the physiological plasma levels are either not detectable or below the micromolar concentrations that are typically employed in vitro ( 32 nM–100  M) in research with human cells. However, tissue resveratrol levels may be higher than what is suggested based on plasma levels because resveratrol is lipophilic. Moreover, resveratrol has shown efficacy at very low concentrations [33] in studies with animal models of human diseases and dramatically opposite effects depending on dose [34]. Our present studies investigated the protective effects of low concentrations of resveratrol on baboon ECs. Additional experiments with baboons are needed to determine if the in vitro effects of resveratrol on inflammation reflect in vivo effects that can be achieved by oral ingestion of resveratrol and if oral ingestion is cardioprotective.

EC migration is an essential process for a variety of vascular functions such as tumour growth, vascular remodelling, and vascular wound healing. Our results indicated that resveratrol at a low concentration ameliorates impairment of BAEC migration induced by TNF- (0.1–50  M). We found that a low concentration of resveratrol had no inhibitory effect on BAEC migration. However, a high concentration (100  M) of resveratrol decreased BAEC migration. In et al. [27] showed that resveratrol inhibited endothelial cell migration at a dose range of 10–100  M in human and bovine brain EC because of its antiangiogenesis properties. Our results also demonstrated that low doses of resveratrol attenuated the impairment of BAEC migration caused by inflammatory conditions, suggesting a mechanism for its anti-inflammatory properties. Cicha et al. [35] observed that resveratrol dose-dependently inhibited EC migration at 1–20  mol/L in a Rho-associated-kinase- (ROCK-) dependent manner. Resveratrol promoted proliferation and migration of cerebral by activation of phosphoinositide 3 kinase (PI3-K)/Akt and mitogen-activated protein kinase (MAPK)/ERK signaling pathways [36]. However, a recent study also revealed that polyphenols from olive oil and red wine reduce inflammatory EC migration in cultured through MMP-9 and COX-2 inhibition [37]. We showed that resveratrol protected BAEC migration from inflammatory conditions. However, the cell specific responses and molecular mechanisms require further investigation to fully resolve the contradictory observations of effects of resveratrol on EC migration.

Inflammation is defined in part by the upregulation of cell adhesion molecules on the surface of in response to cytokines. Adhesion molecule expression is the molecular basis of leukocyte-endothelium interactions and an important characteristic of inflammatory reactions, which are critical in atherogenesis [30]. We investigated the regulation of adhesion molecules by resveratrol with and without TNF- in BAECs. We demonstrated for the first time that resveratrol inhibits TNF- -induced expression of ICAM-1 and VCAM-1 during long-term incubation after TNF- stimulation, as well as by pretreatment and cotreatment. There was no inhibitory effect of resveratrol on CAM expression during short-term incubation, and this characteristic may contribute to its time-dependent inhibition of NF- B [10]. E-selectin, the earliest adhesion molecule upregulated during leukocyte recruitment, was markedly increased after 4-h stimulation. We observed no significant inhibitory effects of resveratrol on the expression of -selectin, which may be restricted by its long-term incubation.

Resveratrol decreased TNF- -induced ICAM-1 and VCAM-1 expression, which may protect cells from TNF- -induced cytotoxicity. However, the underlying molecular mechanisms by which resveratrol exerts its physiological effects require further investigation. Together, our findings highlight the power of resveratrol to protect primary ECs in culture and suggest that resveratrol may offer an alternative therapy for the prevention and treatment of cardiovascular disease. Preclinical trials with baboons are planned to evaluate the protective effects of resveratrol.

5. Conclusions

In summary, our data suggest that resveratrol may protect baboon ECs from cytotoxicity induced by TNF- . Resveratrol may provide a pharmacological approach for suppressing injury under inflammatory conditions and for reducing risk of cardiovascular disease and diabetes.


This study was supported by the National Institutes of Health Grant P01 HL028972; the Natural Science Foundation of Shandong Province (ZR2012HM014, 2010GHZ20201, and 2012GGE27126); the Medical and Health Science and Technology Development Foundation of Shandong Province (2011HD005); National Science and Technology Support Program (2009BAI80B04); the National Natural Science Foundation of China (81100617). It used resources that were supported by the Southwest National Primate Research Center Grant P51 OD011133 from the Office of Research Infrastructure Programs (ORIPs).


  1. H. Walczak, “TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer,” Immunological Reviews, vol. 244, no. 1, pp. 9–28, 2011. View at: Google Scholar
  2. Y. Li, R. F. Schwabe, T. DeVries-Seimon et al., “Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-α and interleukin-6: model of NF-κB- and map kinase-dependent inflammation in advanced atherosclerosis,” Journal of Biological Chemistry, vol. 280, no. 23, pp. 21763–21772, 2005. View at: Publisher Site | Google Scholar
  3. H. Ohta, H. Wada, T. Niwa et al., “Disruption of tumor necrosis factor-α gene diminishes the development of atherosclerosis in ApoE-deficient mice,” Atherosclerosis, vol. 180, no. 1, pp. 11–17, 2005. View at: Publisher Site | Google Scholar
  4. J. K. Aluyen, Q. N. Ton, T. Tran, A. E. Yang, H. B. Gottlieb, and R. A. Bellanger, “Resveratrol: potential as anticancer agent,” Journal of Dietary Supplements, vol. 9, no. 1, pp. 45–56, 2012. View at: Google Scholar
  5. M. C. Recio, I. Andujar, and J. L. Rios, “Anti-inflammatory agents from plants: progress and potential,” Current Medical Chemistry, vol. 19, no. 14, pp. 2088–2103, 2012. View at: Google Scholar
  6. J. M. Wu, T. C. Hsieh, and Z. Wang, “Cardioprotection by resveratrol: a review of effects/targets in cultured cells and animal tissues,” American Journal of Cardiovascular Disease, vol. 1, no. 1, pp. 38–47, 2011. View at: Google Scholar
  7. C. A. Schmitt, E. H. Heiss, and V. M. Dirsch, “Effect of resveratrol on endothelial cell function: molecular mechanisms,” BioFactors, vol. 36, no. 5, pp. 342–349, 2010. View at: Publisher Site | Google Scholar
  8. M. P. Robich, R. M. Osipov, R. Nezafat et al., “Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia,” Circulation, vol. 122, no. 11, pp. S142–S149, 2010. View at: Publisher Site | Google Scholar
  9. M. Crescente, G. Jessen, S. Momi et al., “Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level: functional and modelling studies,” Thrombosis and Haemostasis, vol. 102, no. 2, pp. 336–346, 2009. View at: Publisher Site | Google Scholar
  10. A. Csiszar, K. Smith, N. Labinskyy, Z. Orosz, A. Rivera, and Z. Ungvari, “Resveratrol attenuates TNF-α-induced activation of coronary arterial endothelial cells: role of NF-κB inhibition,” American Journal of Physiology, vol. 291, no. 4, pp. H1694–H1699, 2006. View at: Publisher Site | Google Scholar
  11. R. R. Alcendor, S. Gao, P. Zhai et al., “Sirt1 regulates aging and resistance to oxidative stress in the heart,” Circulation Research, vol. 100, no. 10, pp. 1512–1521, 2007. View at: Publisher Site | Google Scholar
  12. N. C. Whitlock and S. J. Baek, “The anticancer effects of resveratrol: modulation of transcription factors,” Nutrition Cancer, vol. 64, no. 4, pp. 493–502, 2012. View at: Google Scholar
  13. L. Xia, F. Ding, J. H. Zhu, and G. S. Fu, “Resveratrol attenuates apoptosis of pulmonary microvascular endothelial cells induced by high shear stress and proinflammatory factors,” Human Cell, vol. 24, no. 3, pp. 127–133, 2011. View at: Google Scholar
  14. S. Mukherjee, J. I. Dudley, and D. K. Das, “Dose-dependency of resveratrol in providing health benefits,” Dose-Response, vol. 8, no. 4, pp. 478–500, 2010. View at: Publisher Site | Google Scholar
  15. J. Mikula-Pietrasik, A. Kuczmarska, M. Kucińska et al., “Resveratrol and its synthetic derivatives exert opposite effects on mesothelial cell-dependent angiogenesis via modulating secretion of VEGF and IL-8/CXCL8,” Angiogenesis, vol. 15, no. 3, pp. 361–376, 2012. View at: Publisher Site | Google Scholar
  16. P. L. Chen and A. S. Easton, “Anti-angiogenic effects of resveratrol on cerebral angiogenesis,” Current Neurovascular Research, vol. 8, no. 1, pp. 14–24, 2011. View at: Publisher Site | Google Scholar
  17. S. D. Tardif, C. R. Abee, and K. G. Mansfield, “Workshop summary: neotropical primates in biomedical research,” Institute of Laboratory Animal Resources. Vol., No, vol. 52, no. 3, pp. 386–392, 2011. View at: Google Scholar
  18. X. L. Wang, J. Wang, Q. Shi, K. D. Carey, and J. L. VandeBerg, “Arterial wall-determined risk factors to vascular diseases: a nonhuman primate model,” Cell Biochemistry and Biophysics, vol. 40, no. 3, pp. 371–388, 2004. View at: Publisher Site | Google Scholar
  19. D. L. Rainwater, Q. Shi, M. C. Mahaney, V. Hodara, J. L. Vandeberg, and X. L. Wang, “Genetic regulation of endothelial inflammatory responses in baboons,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 8, pp. 1628–1633, 2010. View at: Publisher Site | Google Scholar
  20. Q. Shi, L. A. Cox, J. Glenn et al., “Molecular pathways mediating differential responses to lipopolysaccharide between human and baboon arterial endothelial cells,” Clinical and Experimental Pharmacology & Physiology, vol. 37, no. 2, pp. 178–184, 2010. View at: Publisher Site | Google Scholar
  21. J. K. Bhatt, S. Thomas, and M. J. Nanjan, “Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus,” Nutrition Research, vol. 32, no. 7, pp. 537–541, 2012. View at: Google Scholar
  22. S. Kubota, Y. Ozawa, T. Kurihara, M. Sasaki, K. Yuki, and S. Miyake, “Roles of AMP-activated protein kinase in diabetes-induced retinal inflammation,” Investigative Ophthalmology and Visual Science, vol. 52, no. 12, pp. 9142–9148, 2011. View at: Google Scholar
  23. T. C. Hsieh, X. Lu, J. Guo, and J. M. Wu, “Differential regulation of proliferation, cell cycle control and gene expression in cultured human aortic and pulmonary artery endothelial cells by resveratrol,” International Journal of Molecular Medicine, vol. 26, no. 5, pp. 743–749, 2010. View at: Publisher Site | Google Scholar
  24. A. Cerbulo-Vazquez, M. Zavala, G. A. Perez-Palacios et al., “Baboon fetal arterial endothelial cells are more responsive to challenge by tumor necrosis factor α (TNF-α) than baboon fetal umbilical vein endothelial cells,” Atherosclerosis, vol. 212, no. 2, pp. 701–703, 2010. View at: Publisher Site | Google Scholar
  25. Q. Shi, J. Wang, X. L. Wang, and J. L. VandeBerg, “Comparative analysis of vascular endothelial cell activation by TNF-α and LPS in humans and baboons,” Cell Biochemistry and Biophysics, vol. 40, no. 3, pp. 289–303, 2004. View at: Publisher Site | Google Scholar
  26. Q. Shi, K. Aida, J. L. Vandeberg, and L. W. Xing, “Passage-dependent changes in baboon endothelial cells—relevance to in vitro aging,” DNA and Cell Biology, vol. 23, no. 8, pp. 502–509, 2004. View at: Publisher Site | Google Scholar
  27. K. In, J. Park, and H. Park, “Resveratrol at high doses acts as an apoptotic inducer in endothelial cells,” Cancer Research and Treatment, vol. 38, no. 1, pp. 48–53, 2006. View at: Google Scholar
  28. A. Csiszar, N. Labinskyy, A. Podlutsky et al., “Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations,” American Journal of Physiology, vol. 294, no. 6, pp. H2721–H2735, 2008. View at: Publisher Site | Google Scholar
  29. Z. Ungvari, Z. Orosz, A. Rivera et al., “Resveratrol increases vascular oxidative stress resistance,” American Journal of Physiology, vol. 292, no. 5, pp. H2417–H2424, 2007. View at: Publisher Site | Google Scholar
  30. P. M. Brito, N. F. Simões, L. M. Almeida, and T. C. P. Dinis, “Resveratrol disrupts peroxynitrite-triggered mitochondrial apoptotic pathway: a role for Bcl-2,” Apoptosis, vol. 13, no. 8, pp. 1043–1053, 2008. View at: Publisher Site | Google Scholar
  31. D. J. Boocock, G. E. S. Faust, K. R. Patel et al., “Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent,” Cancer Epidemiology Biomarkers & Prevention, vol. 16, no. 6, pp. 1246–1252, 2007. View at: Publisher Site | Google Scholar
  32. V. A. Brown, K. R. Patel, M. Viskaduraki et al., “Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis,” Cancer Research, vol. 70, no. 22, pp. 9003–9011, 2010. View at: Publisher Site | Google Scholar
  33. P. A. Kroon, A. Iyer, P. Chunduri, V. Chan, and L. Brown, “The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential,” Current Medicinal Chemistry, vol. 17, no. 23, pp. 2442–2455, 2010. View at: Publisher Site | Google Scholar
  34. J. Dudley, S. Das, S. Mukherjee, and D. K. Das, “Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose,” Journal of Nutritional Biochemistry, vol. 20, no. 6, pp. 443–452, 2009. View at: Publisher Site | Google Scholar
  35. I. Cicha, M. Regler, K. Urschel, M. Goppelt-Struebe, W. G. Daniel, and C. D. Garlichs, “Resveratrol inhibits monocytic cell chemotaxis to MCP-1 and prevents spontaneous endothelial cell migration through Rho kinase-dependent mechanism,” Journal of Atherosclerosis and Thrombosis, vol. 18, no. 12, pp. 1031–1042, 2011. View at: Google Scholar
  36. F. Simão, A. S. Pagnussat, J. H. Seo et al., “Pro-angiogenic effects of resveratrol in brain endothelial cells: nitric oxide-mediated regulation of vascular endothelial growth factor and metalloproteinase,” Journal of Cerebral Blood Flow of Metabolism, vol. 32, no. 5, pp. 884–895, 2012. View at: Publisher Site | Google Scholar
  37. E. Scoditti, N. Calabriso, M. Massaro et al., “Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer,” Archives of Biochemistry and Biophysics, vol. 527, no. 2, pp. 81–89, 2012. View at: Google Scholar

Copyright © 2013 Juan Xiao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.